Renal Cell Carcinoma

>

Latest News

The Field of Recurrent RCC Regimens Continues to Grow
The Field of Recurrent RCC Regimens Continues to Grow

June 12th 2024

During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed regimens for recurrent metastatic clear cell renal cell carcinoma including lenvatinib plus everolimus, belzutifan, and investigational cell therapy and bispecific agents in the second article of a 2-part series.

Treatment-Free Survival Lengthened With Nivolumab/Cabozantinib Combination in Patients With Advanced RCC
Treatment-Free Survival Lengthened With Nivolumab/Cabozantinib Combination in Patients With Advanced RCC

June 6th 2024

Berg Discusses Tolerability Challenges of IO/TKI in Advanced RCC
Berg Discusses Tolerability Challenges of IO/TKI in Advanced RCC

June 6th 2024

TLX250-CDx Advances Towards FDA Approval With Completed BLA Submission
TLX250-CDx Advances Towards FDA Approval With Completed BLA Submission

June 5th 2024

Slower Tumor Progression Seen With Lenvatinib Plus Pembrolizumab vs Sunitinib in Advanced RCC
Slower Tumor Progression Seen With Lenvatinib Plus Pembrolizumab vs Sunitinib in Advanced RCC

June 5th 2024

Video Series
Video Interviews
Podcasts

More News